Diagnostic Value of Seven Different Imaging Modalities for Patients with Neuroblastic Tumors: A Network Meta-Analysis

Table 3

Subgroup pairwise meta-analysis for DR of NTs.

Included studies	Comparisons	Heterogeneity assessment		Pairwise meta-analysis
		I^2	Ph	OR (95%CI)	Z	P
Primary tumor
1 study	^123I-MIBG vs. ^18F-FDOPA	NA	NA	0.294 (0.028–3.138)	1.01	0.311
1 study	^123I-MIBG vs. ^18F-FDG	NA	NA	2.355 (0.986–5.621)	1.93	0.054
1 study	^123I-MIBG vs. ^111In-pentetreotide	NA	NA	9.486 (3.484–25.826)	4.40	＜0.001
1 study	^68Ga-SSAs vs. ^131I-MIBG	NA	NA	1.000 (0.232–4.310)	0.00	1.000
2 studies	^18F-FDG vs. ^131I-MIBG	0.0%	0.872	1.533 (0.535–4.396)	0.80	0.427
Bone and bone marrow metastases
1 study	^18F-FDOPA vs. ^123I-MIBG	NA	NA	5.283 (2.325–12.005)	3.97	＜0.001
1 study	^123I-MIBG vs. ^131I-MIBG	NA	NA	0.645 (0.120–3.472)	0.51	0.610
4 studies	^123I-MIBG vs. ^18F-FDG	93.5%	＜0.001	2.402 (0.490–11.781)	1.08	0.280
2 studies	CT or MRI vs. ^123I-MIBG	46.6%	0.171	7.170 (4.503–11.415)	8.30	＜0.001
2 studies	^18F-FDG vs. ^131I-MIBG	95.1%	＜0.001	0.339 (0.004–32.575)	0.46	0.642
1 study	CT or MRI vs. ^18F-FDG	NA	NA	4.525 (2.778–7.353)	6.07	＜0.001
Primary tumor and metastases
2 studies	^18F-FDOPA vs. ^123I-MIBG	26.5%	0.244	5.943 (3.480–10.149)	6.53	＜0.001
1 study	^123I-MIBG vs. ^68Ga-SSAs	NA	NA	0.280 (0.075–1.047)	1.89	0.059
3 studies	^123I-MIBG vs. ^131I-MIBG	66.1%	0.052	1.280 (0.429–3.818)	0.44	0.658
3 studies	^123I-MIBG vs. ^18F-FDG	93.3%	＜0.001	1.541 (0.342–6.938)	0.56	0.573
2 studies	CT or MRI vs. ^123I-MIBG	89.7%	0.002	4.291 (0.813–22.640)	1.72	0.086
2 studies	^18F-FDOPA vs. CT or MRI	80.1%	0.025	1.363 (0.411–4.522)	0.51	0.613
2 studies	^131I-MIBG vs. ^18F-FDG	0.0%	0.797	22.563 (8.020–63.480)	5.90	＜0.001
1 study	CT or MRI vs. ^18F-FDG	NA	NA	4.926 (1.808–13.333)	3.12	0.02
1 study	^131I-MIBG vs. CT or MRI	NA	NA	3.086 (1.350–7.054)	2.67	0.008

NTs, neuroblastic tumors; DR, detection rate.